News Stanford and twoXAR strike deal to take on liver cancer Stanford University School of Medicine is to take on liver cancer by teaming with twoXAR to develop new drug candidates.
News NICE says no to liver cancer drug Nexavar Liver cancer treatment latest earmarked for removal from CDF
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
